#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14890	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1996	738.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1419	1419	C	863	C,T	807,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14890	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1996	738.7	0	HET	.	.	.	T1412TGGGGG,TGGGGGG	.	1412	1412	T	1647	1647	T	838	TGGGGG,TGGGGGG	580,165	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14890	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1996	738.7	0	HET	.	.	.	C1525T	.	1525	1525	C	1760	1760	C	762	C,T	551,142	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27434	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3490	783.3	0	.	n	.	0	T695C	SNP	695	695	T	1017	1017	C	859	C	812	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27434	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3490	783.3	0	.	n	.	0	A1638G	SNP	1638	1638	A	1960	1960	G	960	G	902	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27434	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3490	783.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2293	2293	C	903	C,G	835,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27434	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3490	783.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2367	2367	A	901	A	853	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27434	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3490	783.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2919	2919	C	816	C,G	766,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27434	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3490	783.3	0	HET	.	.	.	A412G	.	412	412	A	734	734	A	901	A,G	607,210	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2120	folP	855	855	100.0	folP.l15.c4.ctg.1	1682	125.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1091	1093	AGC	203;203;203	A;G;C	189;186;185	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5480	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3478	157.2	1	SNP	p	S91F	1	.	.	271	273	TTC	604	606	TTC	179;177;177	T;T;C	168;166;168	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5480	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3478	157.2	1	SNP	p	D95G	1	.	.	283	285	GGC	616	618	GGC	178;177;174	G;G;C	169;166;167	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5480	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3478	157.2	1	SNP	p	G95N	0	.	.	283	285	GGC	616	618	GGC	178;177;174	G;G;C	169;166;167	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1710	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1302	131.0	0	.	p	.	0	F184L	NONSYN	550	552	TTC	861	863	TTG	217;216;217	T;T;G	208;207;206	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1710	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1302	131.0	1	SNP	p	G45D	0	.	.	133	135	GGC	444	446	GGC	203;204;203	G;G;C	191;192;189	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	824	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1207	68.1	0	.	n	.	0	A197.	DEL	197	197	A	726	726	A	197	A	176	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	181.4	1	SNP	p	D86N	0	.	.	256	258	GAC	521	523	GAC	220;219;220	G;A;C	201;194;203	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	181.4	1	SNP	p	R87W	0	.	.	259	261	CGT	524	526	CGT	220;221;222	C,A;G;T	205,1;204;203	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	181.4	1	SNP	p	S87R	1	.	.	259	261	CGT	524	526	CGT	220;221;222	C,A;G;T	205,1;204;203	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	181.4	1	SNP	p	R87I	0	.	.	259	261	CGT	524	526	CGT	220;221;222	C,A;G;T	205,1;204;203	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5344	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2935	181.4	1	SNP	p	S88P	0	.	.	262	264	TCC	527	529	TCC	221;223;225	T;C;C	203;205;208	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4278	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2491	170.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1467	1469	GGC	193;192;192	G;G;C	175;173;173	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1267	1269	GCA	227;226;227	G;C;A	213;212;212	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1270	1272	ATC	228;230;234	A;T;C	210;213;217	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1282	1284	GTG	231;229;227	G;T;G	216;215;215	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1282	1284	GTG	231;229;227	G;T;G	216;215;215	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1786	1788	ACC	204;202;202	A;C;C	179;183;186	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1840	1842	GCG	203;202;201	G;C;G	188;173;177	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1840	1842	GCG	203;202;201	G;C;G	188;173;177	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1963	1965	AGC	174;175;175	A;G;C	162;159;161	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1972	1974	GGC	172;172;167	G;G;C	156;160;152	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4070	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2389	169.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1990	1992	CCG	148;151;158	C,CGG;C;GCCC,GGCCCC	91,2;99;97,2	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5768	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3175	181.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1634	1636	CCG	215;213;217	C;C;G,A	193;194;190,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2274	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1788	126.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	543	543	C	168	C	156	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	322	porB1a	984	112	91.96	porB1a.l6.c17.ctg.1	580	28.9	0	.	p	.	0	M18T	NONSYN	52	54	ATG	441	443	ACG	88;85;83	A;C;G	79;78;76	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	322	porB1a	984	112	91.96	porB1a.l6.c17.ctg.1	580	28.9	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	483	485	CAA	46;44;42	C;A;A	41;39;38	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	322	porB1a	984	112	91.96	porB1a.l6.c17.ctg.1	580	28.9	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	489	491	TAC	35;25;23	T;A;C	34;24;23	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	353	355	GAA	250;253;255	G;A;A	234;240;242	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	641	643	GAT	241;240;240	G;A;T	221;219;221	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	764	766	TCA	226;223;221	T;C;A	217;215;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	893	895	GTC	238;240;242	G;T;C	221;222;225	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	0	.	p	.	0	F222S	NONSYN	664	666	TTT	905	907	TCT	245;242;241	T;C;T	224;222;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1223	1225	GCA	223;220;219	G;C;A	204;199;199	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	1	SNP	p	G120K	1	.	.	358	360	AAG	599	601	AAG	248;247;246	A;A;G	232;229;226	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	1	SNP	p	A121D	1	.	.	361	363	GAC	602	604	GAC	244;244;243	G;A;C	228;223;224	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2890	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1433	199.7	1	SNP	p	D121N	0	.	.	361	363	GAC	602	604	GAC	244;244;243	G;A;C	228;223;224	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	340	porB3	990	116	92.24	porB3.l6.c17.ctg.2	404	34.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	272	274	ACG	73;70;68	A;C;G	66;65;63	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	340	porB3	990	116	92.24	porB3.l6.c17.ctg.2	404	34.6	0	.	p	.	0	T29A	NONSYN	85	87	ACC	305	307	GCC	64;60;57	G;C;C,T	53;52;49,1	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	340	porB3	990	116	92.24	porB3.l6.c17.ctg.2	404	34.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	314	316	CAA	41;39;36	C;A;A	36;34;32	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	340	porB3	990	116	92.24	porB3.l6.c17.ctg.2	404	34.6	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	320	322	TAC	29;19;17	T;A;C	28;18;17	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10568	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4894	215.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1138	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1022	110.5	1	SNP	p	V57M	1	.	.	169	171	ATG	499	501	ATG	247;249;246	A;T;G	234;233;232	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
